L’Oréal USA Inks Deal with 3-D BioPrint Firm

L’Oréal USA has inked a partnership with 3-D bioprinting company, Inc. Developed between L’Oréal’s US-based global Technology Incubator and Organovo, the collaboration will leverage Organovo’s proprietary NovoGen Bioprinting Platform and L’Oréal’s expertise in skin engineering to develop 3-D printed skin tissue for product evaluation and other areas of advanced research.

Organovo’s 3-D bioprinting enables the reproducible, automated creation of living human tissues that mimic the form and function of native tissues in the body. The partnership marks the first-ever application of Organovo’s technology within the beauty industry.

“We developed our technology incubator to uncover disruptive innovations across industries that have the potential to transform the beauty business,” said Guive Balooch, global vice president of L’Oréal’s Technology Incubator. “Organovo has broken new ground with 3-D bioprinting, an area that complements L’Oréal’s pioneering work in the research and application of reconstructed skin for the past 30 years. Our partnership  will not only bring about new, advanced in vitro methods for evaluating product safety and performance, but the potential for where this new field of technology and research can take us is boundless.”  

“We are excited to be partnering with L’Oréal, whose leadership in the beauty industry is rooted in scientific innovation and a deep commitment to research and development,” said Keith Murphy, chairman and chief executive officer at Organovo. “This partnership is a great next step to expand the applications of Organovo’s 3-D bioprinting technology and to create value for both L’Oréal and Organovo by building new breakthroughs in skin modeling.”